Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'dyskinesias' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 281 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bezard, E; Brotchie, JM; Gross, CE
      Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

      NATURE REVIEWS NEUROSCIENCE
    2. Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Grosset, DG; MacMahon, DG; Playfer, J; Schapira, AHV; Stewart, D; Widliams, AC
      Updated guidelines for the management of Parkinson's disease

      HOSPITAL MEDICINE
    3. Bjarkam, CR; Sorensen, JC; Sunde, NA; Geneser, FA; Ostergaard, K
      New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders

      BIOGERONTOLOGY
    4. Wooten, GF
      Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    5. Nutt, JG
      Motor fluctuations and dyskinesia in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    6. Jankovic, J; Tintner, R
      Dystonia and parkinsonism

      PARKINSONISM & RELATED DISORDERS
    7. Lozano, AM
      Deep brain stimulation for Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    8. Dodel, RC; Berger, K; Oertel, WH
      Health-related quality of life and healthcare utilisation in patients withParkinson's disease - Impact of motor fluctuations and dyskinesias

      PHARMACOECONOMICS
    9. Marty, MS; Crissman, JW; Carney, EW
      Evaluation of the male pubertal assay's ability to detect thyroid inhibitors and dopaminergic agents

      TOXICOLOGICAL SCIENCES
    10. Furlanut, M; Furlanut, M; Benetello, P
      Monitoring of L-dopa concentrations in Parkinson's disease

      PHARMACOLOGICAL RESEARCH
    11. Baezner, H; Oster, M; Henning, O; Cohen, S; Hennerici, MG
      Amantadine increases gait steadiness in frontal gait disorder due to subcortical vascular encephalopathy: A double-blind randomized placebo-controlled trial based on quantitative gait analysis

      CEREBROVASCULAR DISEASES
    12. Lee, JI; Shin, HJ; Nam, DH; Kim, JS; Hong, SC; Shin, HJ; Park, K; Eoh, W; Kim, JH; Lee, WY
      Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine

      JOURNAL OF KOREAN MEDICAL SCIENCE
    13. Johansson, PA; Andersson, M; Andersson, KE; Cenci, MA
      Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia

      NEUROBIOLOGY OF DISEASE
    14. Iravani, MM; Costa, S; Jackson, MJ; Tel, BC; Cannizzaro, C; Pearce, RKB; Jenner, P
      GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed commonmarmosets

      EUROPEAN JOURNAL OF NEUROSCIENCE
    15. Roberts, RC
      Effect of chronic olanzapine treatment on striatal synaptic organization

      SYNAPSE
    16. Fox, SH; Henry, B; Hill, MP; Peggs, D; Crossman, AR; Brotchie, JM
      Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan

      MOVEMENT DISORDERS
    17. Rascol, O; Arnulf, I; Paul, HPS; Brefel-Courbon, C; Vidailhet, M; Thalamas, C; Bonnet, AM; Descombes, S; Bejjani, B; Fabre, N; Montastruc, JL; Agid, Y
      Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

      MOVEMENT DISORDERS
    18. Goto, S; Kunitoku, N; Hamasaki, T; Nishikawa, S; Ushio, Y
      Abolition of postapoplectic hemichorea by Vo-complex thalamotomy: Long-term follow-up study

      MOVEMENT DISORDERS
    19. Muriel, MP; Agid, Y; Hirsch, E
      Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease

      MOVEMENT DISORDERS
    20. Ahlskog, JE; Muenter, MD
      Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

      MOVEMENT DISORDERS
    21. Del Dotto, P; Pavese, N; Gambaccini, G; Bernardini, S; Metman, LV; Chase, TN; Bonuccelli, U
      Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

      MOVEMENT DISORDERS
    22. Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M
      Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

      MOVEMENT DISORDERS
    23. Petzinger, GM; Quik, M; Ivashina, E; Jakowec, MW; Jakubiak, M; Di Monte, D; Langston, JW
      Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate

      MOVEMENT DISORDERS
    24. Wu, YR; Levy, R; Ashby, P; Tasker, RR; Dostrovsky, JO
      Does stimulation of the GPi control dyskinesia by activating inhibitory axons?

      MOVEMENT DISORDERS
    25. Hoff, JI; vander Plas, AA; Wagemans, EAH; van Hilten, JJ
      Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease

      MOVEMENT DISORDERS
    26. Ahlskog, JE
      Parkinson's disease: Medical and surgical treatment

      NEUROLOGIC CLINICS
    27. Friedlander, R; Lazar, S; Klancnik, J
      Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    28. Jankovic, J
      Parkinson's diseasetherapy: treatment of early and late disease

      CHINESE MEDICAL JOURNAL
    29. Rascol, O; Fabre, N
      Dyskinesia: L-dopa-induced and tardive dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    30. Greenamyre, JT
      Glutamatergic influences on the basal ganglia

      CLINICAL NEUROPHARMACOLOGY
    31. Jost, WH; Kohl, A
      Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm

      JOURNAL OF NEUROLOGY
    32. Bayas, A; Kornhuber, J; Naumann, M
      Atypical neuroleptics and new antidepressants in the treatment of neurological disorders

      AKTUELLE NEUROLOGIE
    33. Mungersdorf, M; Sommer, U; Sommer, M; Reichmann, H
      High-dose therapy with ropinirole in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    34. Galvez-Jimenez, N; Hanson, MR; Desai, M
      Unusual causes of hemifacial spasm

      SEMINARS IN NEUROLOGY
    35. Mehta, A; Bot, G; Reisine, T; Chesselet, MF
      Endomorphin-1: Induction of motor behavior and lack of receptor desensitization

      JOURNAL OF NEUROSCIENCE
    36. Huang, XM; Lawler, CP; Lewis, MM; Nichols, DE; Mailman, RB
      D-1 dopamine receptors

      INTERNATIONAL REVIEW OF NEUROBIOLOGY, VOL 48
    37. Kim, JS
      Involuntary movements after anterior cerebral artery territory infarction

      STROKE
    38. Bibbiani, F; Oh, JD; Chase, TN
      Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

      NEUROLOGY
    39. Shoulson, I; Penney, J; McDermott, M; Kieburtz, K; Schwid, SR; Kayson, E; Chase, T; Fahn, S; Greenamyre, JT; Lang, A; Siderowf, A; Pearson, N; Harrison, M; Rost-Ruffner, E; Colcher, A; Lloyd, M; Matthews, M; Pahwa, R; McGuire, D; Lew, MF; Schuman, S; Marek, K; Broshjeit, S; Factor, S; Brown, D; Feigin, A; Mazurkiewicz, J; Ford, B; Jennings, D; Dillon, S; Comella, C; Blasucci, L; Janko, K; Shulman, L; Wiener, W; Bateman-Rodriguez, D; Carrion, A; Suchowersky, O; Lafontaine, AL; Pantella, C; Siemers, E; Belden, J; Davies, R; Lannon, M; Grimes, D; Gray, P; Martin, W; Kennedy, L; Adler, C; Newman, S; Hammerstad, J; Stone, C; Lewitt, P; Bardram, K; Mistura, K; Miyasaki, J; Johnston, L; Cha, JHJ; Tennis, M; Panisset, M; Hall, J; Tetrud, J; Friedlander, J; Hauser, R; Gauger, L; Rodnitzky, R; Deleo, A; Dobson, J; Seeberger, L; Dingmann, C; Tarsy, D; Ryan, P; Elmer, L; Ruzicka, D; Stacy, M; Brewer, M; Locke, B; Baker, D; Casaceli, C; Day, D; Florack, M; Hodgeman, K; Laroia, N; Nobel, R; Orme, C; Rexo, L; Rothenburgh, K; Sulimowicz, K; Watts, A; Wratni, E; Tariot, P; Cox, C; Leventhal, C; Alderfer, V; Craun, AM; Frey, J; McCree, L; McDermott, J; Cooper, J; Holdich, T; Read, B
      A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

      NEUROLOGY
    40. Olanow, CW; Watts, RL; Koller, WC
      An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines

      NEUROLOGY
    41. Kulkarni, SK; Naidu, PS
      Tardive dyskinesia: An update

      DRUGS OF TODAY
    42. Millan, MJ; Cussac, D; Milligan, G; Carr, C; Audinot, V; Gobert, A; Lejeune, F; Rivet, JM; Brocco, M; Duqueyroix, D; Nicolas, JP; Boutin, JA; Newman-Tancredi, A
      Antiparkinsonian agent piribedil displays antagonist properties at native,rat, and cloned, human alpha(2)-adrenoceptors: Cellular and functional characterization

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    43. Katayama, Y; Kasai, M; Oshima, H; Fukaya, C; Yamamoto, T; Ogawa, K; Mizutani, T
      Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients

      JOURNAL OF NEUROSURGERY
    44. Manson, AJ; Katzenschlager, R; Hobart, J; Lees, AJ
      High dose naltrexone for dyskinesias induced by levodopa

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    45. Kannari, K; Yamato, H; Shen, H; Tomiyama, M; Suda, T; Matsunaga, M
      Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

      JOURNAL OF NEUROCHEMISTRY
    46. Henry, B; Fox, SH; Crossman, AR; Brotchie, JM
      mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

      EXPERIMENTAL NEUROLOGY
    47. Pirker, W; Tedroff, J; Ponten, H; Gunne, L; Andren, PE; Hurd, YL
      Coadministration of (-)-OSU6162 with L-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions

      EXPERIMENTAL NEUROLOGY
    48. Tahar, AH; Ekesbo, A; Gregoire, L; Bangassoro, E; Svensson, KA; Tedroff, J; Bedard, PJ
      Effects of acute and repeated treatment with a novel dopamine D-2 receptorligand on L-DOPA-induced dyskinesias in MPTP monkeys

      EUROPEAN JOURNAL OF PHARMACOLOGY
    49. Raghavendra, V; Naidu, PS; Kulkarni, SK
      Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors

      BRAIN RESEARCH
    50. Boraud, T; Bezard, E; Bioulac, B; Gross, CE
      Dopamine agonist-induced dyskinesias are correlated to both firing patternand frequency alterations of pallidal neurones in the MPTP-treated monkey

      BRAIN
    51. Manson, AJ; Hanagasi, H; Turner, K; Patsalos, PN; Carey, P; Ratnaraj, N; Lees, AJ
      Intravenous apomorphine therapy in Parkinson's disease - Clinical and pharmacokinetic observations

      BRAIN
    52. Peacock, L; Gerlach, J
      Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: Evidence of uncharted dopamine D1 receptor actions

      BIOLOGICAL PSYCHIATRY
    53. Konradi, C; Heckers, S
      Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia

      BIOLOGICAL PSYCHIATRY
    54. Cubo, E; Gracies, JM; Benabou, R; Olanow, CW; Raman, R; Leurgans, S; Goetz, CG
      Early morning off-medication dyskinesias, dystonia, and choreic subtypes

      ARCHIVES OF NEUROLOGY
    55. Karp, BI; Garvey, M; Jacobsen, LK; Frazier, JA; Hamburger, SD; Bedwell, JS; Rapoport, JL
      Abnormal neurologic maturation in adolescents with early-onset schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    56. Muller, DJ; Schulze, TG; Knapp, M; Held, T; Krauss, H; Weber, T; Ahle, G; Maroldt, A; Alfter, D; Maier, W; Nothen, MM; Rietschel, M
      Familial occurrence of tardive dyskinesia

      ACTA PSYCHIATRICA SCANDINAVICA
    57. Green, CA; Fenn, DS; Moussaoui, D; Kadri, N; Hoffman, WF
      Quality of life in treated and never-treated schizophrenic patients

      ACTA PSYCHIATRICA SCANDINAVICA
    58. Pearce, RKB; Heikkila, M; Linden, IB; Jenner, P
      L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

      PSYCHOPHARMACOLOGY
    59. Lledo, A
      Dopamine agonists: the treatment for Parkinson's disease in the XXI century?

      PARKINSONISM & RELATED DISORDERS
    60. Kondo, T
      Treatment of Parkinson's disease in Japan

      PARKINSONISM & RELATED DISORDERS
    61. Linazasoro, G
      Worsening of Parkinson's disease by citalopram

      PARKINSONISM & RELATED DISORDERS
    62. Dewey, RB; Giller, CA; Broline, SK; Mendelsohn, DB; Lacritz, LH; Cullum, CM
      Clinical outcome of unilateral stereotactic pallidotomy without microelectrode recording for intractable Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    63. Linazasoro, G; Garmendia, MT; Lizaso, X
      Acute dystonia in a young schizophrenic patient associated with ingestion of a cloperastine containing cough syrup

      PARKINSONISM & RELATED DISORDERS
    64. Bonnet, AM
      Involvement of non-dopaminergic pathways in Parkinson's disease - Pathophysiology and therapeutic implications

      CNS DRUGS
    65. Ahlskog, JE
      Treatment of motor complications in advancing Parkinson's disease: Which drugs and when?

      FORMULARY
    66. Marin, C; Jimenez, A; Bonastre, M; Chase, TN; Tolosa, E
      Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats

      SYNAPSE
    67. Poewe, W; Wenning, GK
      Apomorphine: An underutilized therapy for Parkinson's disease

      MOVEMENT DISORDERS
    68. Reuter, I; Harder, S; Engelhardt, M; Baas, H
      The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa

      MOVEMENT DISORDERS
    69. Luginger, E; Wenning, GK; Bosch, S; Poewe, W
      Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease

      MOVEMENT DISORDERS
    70. Di Monte, DA; McCormack, A; Petzinger, G; Janson, AM; Quik, M; Langston, WJ
      Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

      MOVEMENT DISORDERS
    71. Beran-Koehn, MA; Zupanc, ML; Patterson, MC; Olk, DG; Ahlskog, JE
      Violent recurrent ballism associated with infections in two children with static encephalopathy

      MOVEMENT DISORDERS
    72. Fernandez, HH; Lannon, MC; Friedman, JH; Abbott, BP
      Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

      MOVEMENT DISORDERS
    73. Metman, LV; Konitsiotis, S; Chase, TN
      Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

      MOVEMENT DISORDERS
    74. Factor, SA; Molho, ES
      Emergency department presentations of patients with Parkinson's disease

      AMERICAN JOURNAL OF EMERGENCY MEDICINE
    75. Metman, LV; Del Dotto, P; LePoole, K; Konitsiotis, S; Fang, J; Chase, TN
      Amantadine for levodopa-induced dyskinesias

      NERVENHEILKUNDE
    76. Hattori, H; Fujii, T; Nigami, H; Higuchi, Y; Tsuji, M; Hamada, Y
      Co-segregation of benign infantile convulsions and paroxysmal kinesigenic choreoathetosis

      BRAIN & DEVELOPMENT
    77. Hattori, H; Yorifuji, T
      Infantile convulsions and paroxysmal kinesigenic choreoathetosis in a patient with idiopathic hypoparathyroidism

      BRAIN & DEVELOPMENT
    78. Naidu, PS; Kulkarni, SK
      Differential role of dopamine D-1 and D-2 receptors in isoniazid-induced vacuous chewing movements

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    79. Jenner, P
      Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates

      ANNALS OF NEUROLOGY
    80. Hirsch, EC
      Nigrostriatal system plasticity in Parkinson's disease: Effect of dopaminergic denervation and treatment

      ANNALS OF NEUROLOGY
    81. Chase, TN; Oh, JD
      Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications

      ANNALS OF NEUROLOGY
    82. Hallett, M
      Clinical physiology of dopa dyskinesia

      ANNALS OF NEUROLOGY
    83. Brooks, DJ; Piccini, P; Turjanski, N; Samuel, M
      Neuroimaging of dyskinesia

      ANNALS OF NEUROLOGY
    84. Rascol, O
      Medical treatment of levodopa-induced dyskinesias

      ANNALS OF NEUROLOGY
    85. Benabid, AL; Benazzouz, A; Limousin, P; Koudsie, A; Krack, P; Piallat, B; Pollak, P
      Dyskinesias and the subthalamic nucleus

      ANNALS OF NEUROLOGY
    86. Jankovic, J
      Parkinson's disease therapy: Tailoring choices for early and late disease,young and old patients

      CLINICAL NEUROPHARMACOLOGY
    87. Tahar, AH; Gregoire, L; Bangassoro, E; Bedard, PJ
      Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

      CLINICAL NEUROPHARMACOLOGY
    88. Smith, LA; Jackson, MG; Bonhomme, C; Chezaubernard, C; Pearce, RKB; Jenner, P
      Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset

      CLINICAL NEUROPHARMACOLOGY
    89. Chase, TN; Oh, JD; Konitsiotis, S
      Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

      JOURNAL OF NEUROLOGY
    90. Jenner, P
      Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments

      JOURNAL OF NEUROLOGY
    91. Rascol, O
      The pharmacological therapeutic management of levodopa-induced dyskinesiasin patients with Parkinson's disease

      JOURNAL OF NEUROLOGY
    92. Krack, P; Poepping, M; Weinert, D; Schrader, B; Deuschl, C
      Thalamic, pallidal, or subthalamic surgery for Parkinson's disease?

      JOURNAL OF NEUROLOGY
    93. He, L; Di Monte, DA; Langston, JW; Quik, M
      Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and levodopa treatment

      NEUROSCIENCE
    94. Van Kampen, JM; Stoessl, AJ
      Effects of oligonucleotide antisense to dopamine D-1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia

      NEUROSCIENCE
    95. Van Kampen, JM; Stoessl, AJ
      Dopamine D-1A receptor function in a rodent model of tardive dyskinesia

      NEUROSCIENCE
    96. Ruzicka, E; Streitova, H; Jech, R; Kanovsky, P; Roth, J; Rektorova, I; Mecir, P; Hortova, H; Bares, M; Hejdukova, B; Rektor, I
      Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    97. Meredith, GE; De Souza, IEJ; Hyde, TM; Tipper, G; Wong, ML; Egan, MF
      Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias

      JOURNAL OF NEUROSCIENCE
    98. Obeso, JA; Olanow, CW; Nutt, JG
      Levodopa motor complications in Parkinson's disease

      TRENDS IN NEUROSCIENCES
    99. Hirsch, EC; Perier, C; Orieux, G; Francois, C; Feger, J; Yelnik, J; Vila, M; Levy, R; Tolosa, ES; Marin, C; Herrero, MT; Obeso, JA; Agid, Y
      Metabolic effects of nigrostriatal denervation in basal ganglia

      TRENDS IN NEUROSCIENCES
    100. Chase, TN; Oh, JD
      Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

      TRENDS IN NEUROSCIENCES


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 14:39:11